CIK 0000873303 · Large accelerated filer
Sarepta Therapeutics, Inc.
Sign in to watch- Ticker
- SRPT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 930797222
- Phone
- 617-274-4000
- Business address
- 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
- Former names
- Sarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Rodino-Klapac Louise Head of R&D, CSO | Grant or award | +8,276 | 84,631 | ||
| 2025-03-10 | Rodino-Klapac Louise Head of R&D, CSO | Grant or award · Stock Options (right to buy) | +16,644 | 16,644 | ||
| 2025-03-10 | Nicaise Claude Director | Grant or award | +2,383 | 20,557 | ||
| 2025-03-10 | Nicaise Claude Director | Grant or award · Stock Options (right to buy) | +4,792 | 20,557 | ||
| 2025-03-10 | Estepan Ian Michael Chief Financial Officer | Shares withheld for taxes | −1,051 | $100.13 | $105K | 57,226 |
| 2025-03-10 | Estepan Ian Michael Chief Financial Officer | Shares withheld for taxes | −2,890 | $100.13 | $289K | 54,336 |
| 2025-03-10 | Estepan Ian Michael Chief Financial Officer | Grant or award | +8,276 | 62,612 | ||
| 2025-03-10 | Estepan Ian Michael Chief Financial Officer | Grant or award · Stock Options (right to buy) | +16,644 | 16,644 | ||
| 2025-03-10 | Murray Dallan Chief Customer Officer | Shares withheld for taxes | −996 | $100.13 | $100K | 32,663 |
| 2025-03-10 | Murray Dallan Chief Customer Officer | Shares withheld for taxes | −2,737 | $100.13 | $274K | 29,926 |
| 2025-03-10 | Murray Dallan Chief Customer Officer | Grant or award | +8,276 | 38,202 | ||
| 2025-03-10 | Murray Dallan Chief Customer Officer | Grant or award · Stock Options (right to buy) | +16,644 | 16,644 | ||
| 2025-03-10 | Barry Richard Director | Grant or award | +2,383 | 2,934,071 | ||
| 2025-03-10 | Barry Richard Director | Grant or award · Stock Options (right to buy) | +4,792 | 4,792 | ||
| 2025-03-10 | BEHRENS M KATHLEEN Director | Grant or award | +2,383 | 193,476 | ||
| 2025-03-10 | BEHRENS M KATHLEEN Director | Grant or award · Stock Option (right to buy) | +4,792 | 4,792 | ||
| 2025-03-07 | Rodino-Klapac Louise Head of R&D, CSO | Option exercise | +5,500 | 79,818 | ||
| 2025-03-07 | Rodino-Klapac Louise Head of R&D, CSO | Option exercise · Performance Stock Units | −5,500 | 0 | ||
| 2025-03-07 | Estepan Ian Michael Chief Financial Officer | Option exercise | +5,500 | 58,277 | ||
| 2025-03-07 | Estepan Ian Michael Chief Financial Officer | Option exercise · Performance Stock Units | −5,500 | 0 |
Page 6 of 12 · 227 trades